drugset / Trial / NCT03792516
Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)
Phase 1
Completed
15 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Frantz Viral Therapeutics, LLC · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I, proof-of-concept treatment study to evaluate the safety, tolerability and feasibility of topical artesunate ointment to treat high grade vulvar intraepithelial neoplasia (HSIL VIN2/3).
Timeline
- Start
- 2019-04-17
- Primary completion
- 2022-08-31
- Completion
- 2024-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 40 % | Topical |